**Navigating the Complex Journey of Metastatic Breast Cancer: Insights from Medical Experts and Survivors**
:max_bytes(150000):strip_icc():format(jpeg)/breast-cancer411-000-eee792b5ee114958a85a32d9226df1db.jpg)
In a candid discussion on the challenges of breast cancer diagnosis and recurrence, Dr. Thaïs Aliabadi, an obstetrician-gynaecologist and breast cancer survivor, along with Dr. Elizabeth Comen, a renowned breast oncologist at NYU Langone Health, share invaluable insights about managing metastatic breast cancer. Their perspectives highlight the importance of self-advocacy, understanding the nuances of cancer recurrence, and the advancements in treatment options.
Dr. Aliabadi, who co-hosts the SHE MD podcast, reflects on her own unexpected journey with breast cancer. At the age of 48, she underwent a routine mammogram that indicated atypical cells, sparking her concern despite a lack of family history or known genetic mutations. With risk factors such as dense breast tissue, Aliabadi sought a preventive double mastectomy. However, her path to surgery was fraught with difficulty. “I was told I was too healthy, too anxious, too aggressive,” she explained. Ultimately, it took six months and considerable perseverance to find a surgeon willing to perform the procedure.
Following her surgery, Aliabadi received the shocking news that she had stage 1 invasive breast cancer in a breast that had previously been deemed less concerning. Compelled by her instincts, she noted abnormalities post-surgery and insisted on further examinations, leading to a second double mastectomy. “I had a medical degree, the knowledge and the access, and I still had to fight to be heard,” she said, articulating a shared concern for those who might not have similar resources.
Dr. Comen clarified that metastatic breast cancer, often referred to as stage 4, is characterised by the spread of breast cancer cells beyond their original site to other parts of the body, such as bones, liver, or lungs. It is crucial to understand that this type of cancer is still fundamentally breast cancer, even when found in other organs. “It is breast cancer that has spread to the lung,” she stated, noting that the biology of the cancer cells is pivotal in determining treatment, rather than solely their anatomical locations.
A significant hurdle in the fight against breast cancer is the recurrence of the disease, which often prompts dismay among patients. Many struggle with the question of how cancer can return after following medical advice and undergoing treatment. “Some cancer cells may have already migrated outside the breast before the initial diagnosis,” Dr. Comen explained. While therapies may successfully eliminate the visible cancer, dormant cells can reactivate, leading to recurrence. According to Dr. Aliabadi, “Recurrence is not a failure. It is the biology of cancer.”
Beyond the daunting label of stage 4, Dr. Comen emphasises that not all metastatic conditions are equivalent. For instance, stage 4 pancreatic cancer generally carries a poorer prognosis than stage 4 breast cancer. However, advancements in research have transformed how doctors approach treatment for metastatic breast cancer. Personalised, targeted therapies based on the individual’s unique cancer characteristics are now commonplace, allowing many patients to manage their condition over extended periods without significantly compromising their quality of life.
For those facing metastatic diagnoses, understanding the biology of their cancer can be crucial. In cases of recurrence or when cancer is found in new locations, oncologists often perform biopsies to ascertain the origin and specifics of the tumour, aiding in the selection of appropriate treatments. Recognising changes in the cancer’s biology is essential for developing effective strategies to combat its progression.
Dr. Aliabadi’s journey underscores the imperative for patients to advocate for their health. She urges individuals to familiarise themselves with their breast health, which includes understanding personal risk factors, being aware of breast density, and engaging in informed discussions about screening protocols. Even with normal imaging results, she advocates for seeking further evaluations when new or persistent symptoms arise.
The message is clear: prioritising self-advocacy is vital, and patients shouldn’t hesitate to ask questions or request second opinions. “I want women to stop apologising for asking questions,” Aliabadi insists, noting that many remain silent out of fear of seeming overly dramatic. Her own experience as a doctor and patient reinforces the importance of persisting in the pursuit of answers and adequate care.
For those living with metastatic breast cancer, both experts agree that compassion and support are essential. Dr. Comen notes that living with metastatic disease doesn’t equate to an immediate end, as research continues to pave the way for innovative treatments. Aliabadi encapsulates this sentiment by stating, “Every woman with metastatic disease deserves compassion, support, and better treatments.”
In summarising the journey through breast cancer, it is clear that understanding the complexities of diagnosis and treatment can empower both patients and their caretakers. The ongoing developments in the medical field offer a glimmer of hope for many, highlighting the importance of advocacy, awareness, and personalised care in the fight against breast cancer.